Temporal trends in anxiety and depression prevalence and their association with adverse outcomes in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease in Beijing, China, from 2004 to 2020

Lin, Feng; Li, Jiachen; Lv, Xiaoshuang; Chu, Shuilian; Li, Changwei; Zhang, Ruiyuan; Chen, Xi; Liang, Lirong

doi:10.3389/fpsyt.2022.996451

Cited by 3 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 5 COPD patients with anxiety often experience more frequent exacerbations that lead to longer hospital stays, higher medical costs, higher risks of readmission for acute exacerbation of COPD (AECOPD), and even higher mortality. 6–10 It has been reported that the prevalence of anxiety among inpatients with COPD is 10%–55%, and this is 13%–46% among outpatients, 11 although this might be underestimated, including in China. 8 …”

Section: Introductionmentioning

confidence: 99%

Reliability, Validity, Modification and Expansion of the Chinese Version of the Disease-Specific Anxiety Questionnaire for Chronic Obstructive Pulmonary Disease

Miao,

Han,

et al. 2024

COPD

View full text Add to dashboard Cite

Purpose To translate a disease-specific anxiety questionnaire on chronic obstructive pulmonary disease (COPD) and test its reliability and validity in China. Patients and Methods The German version of the revised COPD Anxiety Questionnaire (CAF-R) was initially validated using step-by-step translation, back-translation, and cross-cultural adaptation. The reliability and validity of the Chinese version of the CAF-R (CAF-R-CN) were tested among 448 patients with COPD (mean age =71.42±9.33 years, 17.2% female) from four medical institutions in Suzhou, Jiangsu Province, using convenience sampling, from April 2022 to June 2023. Results The CAF-R-CN included six dimensions with a total of 25 items. The item-level content validity index was 0.860–1.000; the scale-level content validity index was 0.920. The structural validity χ 2 /df was 2.326, the root mean square error of approximation was 0.077, the comparative fit index was 0.924, and the Tucker–Lewis index was 0.912. The six-dimensional internal consistency index Cronbach’s α coefficient was 0.696–0.910, and the test–retest reliability was 0.949. An optimal cut-off score of 50.5 was selected with a sensitivity of 0.786 and specificity of 0.870. Conclusion The CAF-R-CN had satisfactory reliability and validity and can be used to identify and assess anxiety in COPD patients with a Chinese cultural background.

show abstract

Section: Introductionmentioning

confidence: 99%

Reliability, Validity, Modification and Expansion of the Chinese Version of the Disease-Specific Anxiety Questionnaire for Chronic Obstructive Pulmonary Disease

Miao,

Han,

et al. 2024

COPD

View full text Add to dashboard Cite

show abstract

Effects of Chinese herbal medicine on Patients with AECOPD Risk Window: study protocol for a Randomized Controlled Trial

Hailong,

Huanrong,

guixiang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Chronic Obstructive Pulmonary Disease (COPD) is a major chronic disease with high incidence, mortality, and prevalence. Acute exacerbations mostly occur in a centralized period after an acute exacerbation, during which are extremely easy to occur again. We call this “high-risk period” as the “AECOPD risk window” (AECOPD-RW). At present, Western medicine lacks specific guidance on the medication of AECOPD-RW. Chinese herbal medicine has good efficacy and advantages in the treatment of COPD. Based on the clear distribution of syndrome in the previous period, this study aims to evaluate the clinical efficacy and safety of Chinese herbal medicine on AECOPD-RW. Methods This proposed study is a multi-center, double-blind, randomized controlled trial (RCT) to compare the efficacy of two therapies for patients with AECOPD-RW. 336 subjects will be randomly assigned in a 1:1 ratio to experimental group or control group for 8 weeks treatment and 18 weeks follow-up. Based on health education and conventional treatment, the experimental group will receive Chinese herbal medicine granule according to Chinese medicine syndrome types, while the control group will receive Chinese herbal medicine placebo granule according to Chinese medicine syndrome types. The primary outcomes are acute exacerbation rate in the AECOPD-RW, COPD Assessment Test (CAT) in the AECOPD-RW, and secondary outcomes include time to the first acute exacerbation, degree of acute exacerbation in the AECOPD-RW, acute exacerbation rate in the follow-up period, degree of acute exacerbation in the follow-up period, lung function, mMRC, quality of life and index of security. Outcome measurements will be evaluated at week 0, 8 of the treatment period and at week 16, 26 of the follow-up period. The results will provide evidence for the clinical efficacy and safety of traditional Chinese medicine in the treatment of AECOPD RW, and provide a reliable scheme for the treatment of AECOPD-RW. Discussion This is the first multicenter, randomized, double-blind, placebo-controlled parallel trial designed to investigate the efficacy of Chinese herbal medicine in the treatment of AECOPD-RW. The result of this RCT may help effectively reduce the possibility of AECOPD recurrence, change the course of disease deterioration, and provide evidence-based evidence for Chinese herbal medicine prevention and treatment of AECOPD-RW. Trial registration This trial was registered in ClinicalTrials.gov, NCT04851093. Registered on 14 April 2021.

show abstract

Anxiety, Depression and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease

Li¹,

Xiang²,

Wang³

et al. 2023

JBM

View full text Add to dashboard Cite

Background: Chronic Obstructive Pulmonary Disease (COPD) is a common and frequently occurring disease, which not only has a higher fatality rate, but also leads to loss of labor force and an obvious decrease in the quality of life in the course of long-term disease, patients with chronic obstructive pulmonary disease complicated with anxiety and depression are a major public health problem. Objective: To investigate the status of anxiety, depression and quality of life and related factors in patients with COPD. Methods: One hundred patients admitted to the Department of Respiratory and Critical Care Medicine of the First Affiliated Hospital of Dali University with chronic obstructive pulmonary disease evaluated by anxiety self-assessment scale, depression self-assessment scale and quality of life rating scale for patients with chronic obstructive pulmonary disease. Results: The incidence of anxiety in COPD patients was 82.5%, and the incidence of depression was 87.3%. The probability of both anxiety and depression was high, and the prevalence of women was significantly higher than that of men. Correlation analysis and logistic regression results showed that education level was negatively correlated with the occurrence of anxiety, and age was positively correlated with the occurrence of anxiety. Elderly patients were prone to anxiety and had lower quality of life. Conclusion: The older and less educated the COPD patients are, the higher the incidence of anxiety and depression, and the higher the incidence in female patients.

show abstract

Temporal trends in anxiety and depression prevalence and their association with adverse outcomes in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease in Beijing, China, from 2004 to 2020

Cited by 3 publications

References 39 publications

Reliability, Validity, Modification and Expansion of the Chinese Version of the Disease-Specific Anxiety Questionnaire for Chronic Obstructive Pulmonary Disease

Reliability, Validity, Modification and Expansion of the Chinese Version of the Disease-Specific Anxiety Questionnaire for Chronic Obstructive Pulmonary Disease

Effects of Chinese herbal medicine on Patients with AECOPD Risk Window: study protocol for a Randomized Controlled Trial

Anxiety, Depression and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease

Contact Info

Product

Resources

About